Actuate Therapeutics (ACTU) Competitors $6.65 -0.37 (-5.27%) Closing price 04:00 PM EasternExtended Trading$6.67 +0.02 (+0.30%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACTU vs. ORKA, ARVN, OLMA, ESPR, ANAB, OPT, CMPX, IVA, KOD, and ARCTShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Oruka Therapeutics (ORKA), Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Esperion Therapeutics (ESPR), AnaptysBio (ANAB), Opthea (OPT), Compass Therapeutics (CMPX), Inventiva (IVA), Kodiak Sciences (KOD), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors Oruka Therapeutics Arvinas Olema Pharmaceuticals Esperion Therapeutics AnaptysBio Opthea Compass Therapeutics Inventiva Kodiak Sciences Arcturus Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Do institutionals and insiders hold more shares of ACTU or ORKA? 56.4% of Oruka Therapeutics shares are held by institutional investors. 69.3% of Actuate Therapeutics shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ACTU or ORKA more profitable? Actuate Therapeutics' return on equity of 0.00% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -281.83% Oruka Therapeutics N/A -26.26%-24.16% Does the media favor ACTU or ORKA? In the previous week, Oruka Therapeutics had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 18 mentions for Oruka Therapeutics and 17 mentions for Actuate Therapeutics. Oruka Therapeutics' average media sentiment score of 0.80 beat Actuate Therapeutics' score of 0.05 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ACTU or ORKA? Actuate Therapeutics currently has a consensus price target of $20.33, indicating a potential upside of 205.76%. Oruka Therapeutics has a consensus price target of $42.00, indicating a potential upside of 179.07%. Given Actuate Therapeutics' higher probable upside, equities analysts plainly believe Actuate Therapeutics is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has higher valuation & earnings, ACTU or ORKA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/AOruka TherapeuticsN/AN/A-$83.72M-$2.81-5.36 SummaryOruka Therapeutics beats Actuate Therapeutics on 7 of the 11 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.17M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.77%4.64%P/E RatioN/A20.6375.7726.11Price / SalesN/A442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book665.009.6212.876.30Net Income-$27.28M-$52.73M$3.29B$271.03M7 Day Performance-3.06%0.64%-0.26%-0.15%1 Month Performance-16.67%6.31%3.84%6.41%1 Year Performance14.66%18.97%68.35%28.81% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate Therapeutics2.3975 of 5 stars$6.65-5.3%$20.33+205.8%+7.7%$163.17MN/A0.0010Trending NewsAnalyst ForecastAnalyst RevisionORKAOruka Therapeutics2.6219 of 5 stars$15.45+1.2%$40.33+161.1%-36.0%$579.74MN/A-5.51N/AAnalyst RevisionARVNArvinas3.3097 of 5 stars$7.61-1.7%$19.76+159.7%-68.7%$560.55M$372.80M-7.56420News CoverageAnalyst DowngradeInsider TradeBuyback AnnouncementOLMAOlema Pharmaceuticals2.7072 of 5 stars$8.08+1.0%$24.00+197.0%-33.8%$552.40MN/A-4.0770ESPREsperion Therapeutics3.9547 of 5 stars$2.73-2.0%$7.00+156.9%+47.3%$549.41M$332.31M-5.56200News CoverageANABAnaptysBio2.1743 of 5 stars$19.88-1.4%$46.13+132.0%-36.5%$549.39M$91.28M-4.38100OPTOpthea0.5011 of 5 stars$3.41flat$1.33-60.9%-12.3%$524.84M$87.67K0.008Positive NewsGap UpHigh Trading VolumeCMPXCompass Therapeutics2.6034 of 5 stars$3.74+1.2%$13.88+271.5%+104.1%$519.24M$850K-8.3420IVAInventiva3.0461 of 5 stars$5.40+1.6%$14.83+174.9%+153.2%$516.10M$9.20M0.00100Gap UpKODKodiak Sciences2.8331 of 5 stars$9.57+2.3%$11.75+22.8%+493.5%$505.51MN/A-2.5290News CoverageAnalyst ForecastGap UpARCTArcturus Therapeutics2.7113 of 5 stars$18.48+1.9%$50.57+173.7%-5.9%$504.90M$152.31M-8.34180 Related Companies and Tools Related Companies ORKA Competitors ARVN Competitors OLMA Competitors ESPR Competitors ANAB Competitors OPT Competitors CMPX Competitors IVA Competitors KOD Competitors ARCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACTU Stock Alerts